697-89-2

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-4-iodoaniline is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2,6-dichloro-4-iodoaniline serves as a key intermediate in the production of various agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields and quality.
Used in Dye Industry:
2,6-Dichloro-4-iodoaniline is utilized as a starting material in the synthesis of dyes for various applications, including textiles, plastics, and printing inks. Its distinctive color properties and compatibility with different substrates make it a versatile component in the creation of a wide range of dyes with specific color characteristics and performance attributes.

InChI:InChI=1/C6H4Cl2IN/c7-4-1-3(9)2-5(8)6(4)10/h1-2H,10H2

Upstream product

• 608-31-1 2,6-Dichloroaniline 

Downstream Products

• 108294-54-8 1-benzoyl-3-(2,6-dichloro-4-iodophenyl)thiourea 
• 336194-95-7 (6-chloro-2-methyl-pyrimidin-4-yl)-(2,6-dichloro-4-iodo-phenyl)-amine 
• 336194-97-9 N-cyclopropylmethyl-N'-(2,6-dichloro-4-iodo-phenyl)-2-methyl-N-propyl-pyrimidine-4,6-diamine 
• 134006-32-9 3,5-dichlorobiphenyl-4-ylamine 
• 1131736-91-8 10-chloro-N-(2,6-dichloro-4-iodophenyl)pyrido[4,3-c]-1,6-naphthyridin-6-amine 
• 1131736-67-8 N-(2,6-dichloro-4-iodophenyl)-10-ethoxypyrido[4,3-c]-1,6-naphthyridin-6-amine 
• 1375008-21-1 1-⁽¹³⁾C-(E)-1-(4-amino-3,5-dichlorophenyl)-3-butoxyprop-2-en-1-one 
• 1375008-10-8 (E)-1-(4-amino-3,5-dichlorophenyl)-3-butoxyprop-2-en-1-one 
• 1319805-93-0 1-⁽¹³⁾C-1-(4-amino-3,5-dichlorphenyl)ethanone 
• 1386820-25-2 [1,2-⁽¹³⁾C₂]-2-(4-amino-3,5-dichlorophenyl)-N-(tert-butyl)-2-oxoacetamide 
• 37148-27-9 clenbuterol 
• 75136-79-7 2-(4-amino-3,5-dichlorophenyl)-N-(tert-butyl)-2-oxoacetamide 
• 62909-66-4 4-Amino-3,5-dichlorobenzaldehyde 

Relevant academic research and scientific papers

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles

Molecular hybridization is a powerful strategy in drug discovery. A series of novel diarylbenzopyrimidine (DABP) analogues were developed by the hybridization of FDA-approved drugs etravirine (ETR) and efavirenz (EFV) as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Substituent modifications resulted in the identification of new DABPs with the combination of the strengths of the two drugs, especially compound 12d, which showed promising activity toward the EFV-resistant K103N mutant. 12d also had a favorable pharmacokinetic (PK) profile with liver microsome clearances of 14.4 μL/min/mg (human) and 33.2 μL/min/mg (rat) and an oral bioavailability of 15.5% in rat. However, its activity against the E138K mutant was still unsatisfactory; E138K is the most prevalent NNRTI resistance-associated mutant in ETR treatment. Further optimizations resulted in a highly potent compound (12z) with no substituents on the phenyl ring and a 2-methyl-6-nitro substitution pattern on the 4-cyanovinyl-2,6-disubstitued phenyl motif. The antiviral activity of this compound was much higher than those of ETR and EFV against the WT, E138K, and K103N variants (EC50 = 3.4, 4.3, and 3.6 nM, respectively), and the cytotoxicity was decreased while the selectivity index (SI) was increased. In particular, this compound exhibited acceptable intrinsic liver microsome stability (human, 34.5 μL/min/mg; rat, 33.2 μL/min/mg) and maintained the good PK profile of its parent compound EFV and showed an oral bioavailability of 16.5% in rat. Molecular docking and structure-activity relationship (SAR) analysis provided further insights into the binding of the DABPs with HIV-1 reverse transcriptase and provided a deeper understanding of the key structural features responsible for their interactions.

A practical iodination of aromatic compounds by using iodine and iodic acid

This article describes simple and efficient method for the iodination of different aromatic amines, hydroxy aromatic aldehydes, hydroxy acetophenones and phenols using iodine and iodic acid in ethanol as a solvent. Notable advantages include mild reaction condition, no need of catalyst, short reaction time, simple practical procedure, giving excellent yield of the product. Copyright Taylor & Francis Group, LLC.

Convenient and efficient method for the iodination of aromatic amines by pyridinium iodochloride

A simple and efficient method for the iodination of aromatic amines using pyridinium iodochloride (PyICl) in methanol as solvent is reported. Mild reaction conditions, short reaction time, and good to excellent yields of the product are the noteworthy advantages of the method. Pyridinium iodochloride is an efficient solid iodinating reagent and can be handled safely. Copyright Taylor & Francis Group, LLC.

Iodination of aromatic compounds using potassium iodide and hydrogen peroxide

A simple, efficient, regioselective, and ecofriendly method for oxyiodination of aromatic compounds is presented. In this method, the electrophilic substitutions of iodine generated in situ from KI as an iodine source and hydrogen peroxide as an oxygen source have been employed without any catalyst/mineral acid for the first time. Copyright Taylor & Francis Group, LLC.

Eco-friendly oxyiodination of aromatic compounds using ammonium iodide and hydrogen peroxide

A new eco-friendly procedure for the oxyiodination of aromatic compounds with NH4I as an iodine source and H2O2 as an oxidant without any catalyst is presented.

SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS

Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3-C8)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted β-naphthyl, bicyclic heterocyclic aryl, (C3-C6)cycloalkylmonocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.